TipRanks Cyber Monday Sale
- Claim 60% off TipRanks Premium for data-backed insights and research tools you need to invest with confidence.
- Subscribe to TipRanks' Smart Investor Picks and see our data in action through our high-performing model portfolio - now also 60% off
Galectin Therapeutics ( (GALT) ) just unveiled an announcement.
On December 3, 2025, Galectin Therapeutics presented compelling results from its NAVIGATE trial at its Annual Meeting of Stockholders. The trial focused on belapectin’s efficacy in treating MASH cirrhosis and portal hypertension, showing significant benefits in reducing liver stiffness and varices compared to placebo. The company highlighted the trial’s adaptive design and the decision to unblind data in 2024, which led to extensive data analysis throughout 2025. Key findings included belapectin’s impact on fibrosis and inflammation markers, with no drug-related serious adverse events reported. The results reinforce belapectin’s potential to change the treatment landscape for patients with no FDA-approved therapy, and Galectin is anticipating FDA feedback and exploring strategic opportunities to maximize program value.
The most recent analyst rating on (GALT) stock is a Buy with a $6.00 price target. To see the full list of analyst forecasts on Galectin Therapeutics stock, see the GALT Stock Forecast page.
Spark’s Take on GALT Stock
According to Spark, TipRanks’ AI Analyst, GALT is a Underperform.
Galectin Therapeutics is a high-risk investment due to its challenging financial position, characterized by no revenues and high financial losses. However, the company’s progress in clinical trials and potential partnerships offer a positive long-term outlook. Technical indicators suggest mixed short-term momentum, while traditional valuation metrics are less applicable due to ongoing losses and the absence of dividends.
To see Spark’s full report on GALT stock, click here.
More about Galectin Therapeutics
Galectin Therapeutics Inc. operates within the biotechnology industry, focusing on developing therapies for fibrotic disease and cancer. The company’s primary product is belapectin, which targets liver fibrosis and cirrhosis, particularly in patients with MASH cirrhosis and portal hypertension.
Average Trading Volume: 349,507
Technical Sentiment Signal: Buy
Current Market Cap: $352.1M
Learn more about GALT stock on TipRanks’ Stock Analysis page.